In this article, we referred to Neuraxo Biopharmaceuticals' Cordaneurin therapy as a combination therapy consisting of treatment with a cyclic AMP analogue together with a suppressor of collagen synthesis. Cordaneurin, in fact, consists solely of desferrioxamine as the active pharmaceutical ingredient, in a novel sustained release formulation for local application. Desferrioxamine is approved for human use in iron overload diseases and is an iron chelator that also prevents collagen scarring (S. Hermanns, Neuraxo, personal communication).
